Early changes of plasma lipids during treatment with atypical antipsychotics

International Clinical Psychopharmacology

Volumn 21, Issue 6, 2006, Pages 369-372

  Rettenbacher, Maria A ^a   Ebenbichler, Christoph ^b   Hofer, Alex ^a   Kemmler, Georg ^a   Baumgartner, Susanne ^a   Edlinger, Monika ^a   Hummer, Martina ^a   Lechleitner, Monika ^b   Wolfgang Fleischhacker, W ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antipsychotics; Lipid metabolism; Metabolic disturbances; Schizophrenia; Side effects

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; METABOLIC DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CLOZAPINE; HUMANS; LIPIDS; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SULPIRIDE; THIAZOLES; TIME FACTORS; TRIGLYCERIDES;

EID: 33749359962     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000224786.75664.3b     Document Type: Article

References (19)

1. Assmann G, Nofer JR (2003). Atheroprotective effects of high-density lipoproteins. Ann Rev Med 54:321-341.
2. Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT, et al. (2001). Endocrine and metabolic abnormalities in involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 34:223-231.
3. Baymiller SP, Ball P, McMahon RP, Buchanan RW (2003). Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 59:49-57.
4. Eder-Ischia U, Ebenbichler C, Fleischhacker WW (2005). Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism. Ess Psychopharmacol 6:112-117.
5. Harvey PD, Bowie CR (2005). Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. Exp Opin Pharmacother 6:337-346.
6. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. (2000). Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975-981.
7. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW (1995). Weight gain induced by clozapine. Eur Neuropsychopharmacol 5:437-440.
8. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM (2001). The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 62:347-349.
9. Lambert M, Haro JM, Novick D, Edgell ET, Kennedy L, Ratcliffe M, et al. (2005). Olanzapine vs. other antipsychotics in actual out-patient setting six months tolerability results from the European Schizophrenia Out-Patient Health Outcomes Study. Acta Psychiatr Scand 111:232-243.
10. Lamon-Fava S, Wilson PW, Schaefer EJ (1996). Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arteriscler Thromb Vasc Biol 16:1509-1515.
11. LeFevre PD (2001). Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism? Scott Med J 46:11-13.
12. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353/12:1209-1223.
13. Melkersson K, Dahl ML (2004). Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64:701-732.
14. Meyer JM (2001a). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 62 (Suppl 27):27-34.
15. Meyer JM (2001b). Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369-374.
16. Meyer JM, Koro CE (2004). The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1-17.
17. Mortensen PB, Juel K (1993). Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 163:183-189.
18. Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000). Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 45:21-28.
19. Paton C, Esop R, Young C, Taylor D (2004). Obesity, dyslipidaemia and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 110:299-305.